Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors

Investigational New Drugs, Jul 2017

Jeffrey R. Infante, Roger B. Cohen, Kevin B. Kim, Howard A. Burris, Gregory Curt, Ugochi Emeribe, Delyth Clemett, Helen K. Tomkinson, Patricia M. LoRusso

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.1007%2Fs10637-017-0479-3.pdf

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors

The article A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors, written by Jeffrey R. Infante, Roger B. Cohen, Kevin B. Kim, Howard A. Burris III, Gregory Curt, Ugochi Emeribe, Delyth Clemett, Helen K. Tomkinson, and Patricia M. LoRusso, was originally published electronically on the publisher's internet portal (currently SpringerLink) on April Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors Jeffrey R. Infante 0 1 2 4 5 6 Roger B. Cohen 0 1 2 4 5 6 Kevin B. Kim 0 1 2 4 5 6 Howard A. Burris III 0 1 2 4 5 6 Gregory Curt 0 1 2 4 5 6 Ugochi Emeribe 0 1 2 4 5 6 Delyth Clemett 0 1 2 4 5 6 Helen K. Tomkinson 0 1 2 4 5 6 Patricia M. LoRusso 0 1 2 4 5 6 0 Fox Chase Cancer Center , 333 Cottman Avenue, Philadelphia, PA 19111 , USA 1 Tennessee Oncology, PLLC , 250 25th Ave North, Nashville, TN 37203 , USA 2 Sarah Cannon Research Institute , 93 Harley St, Marylebone, London W1G 6AD , UK 3 Jeffrey R. Infante 4 Yale Cancer Center , 55 Park Street, Ste First Floor, New Haven, CT 06519 , USA 5 AstraZeneca , Charter Way, Macclesfield SK10 2NA , UK 6 California PacificMedical Center (Sutterhealth) , 475 Brannan Street, Suite 220, San Francisco, CA 94107 , USA - The online version of the original article can be found at http://dx.doi.org/ 10.1007/s10637-017-0459-7 With the author(s)’ decision to opt for Open Choice the copyright of the article changed on July 03, 2017 to © The Author(s) 2017 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/ by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. The original article has been corrected. Open Access This article is distributed under the terms of the Creative C o m m o n s A t t r i b u t i o n 4 . 0 I n t e r n a t i o n a l L i c e n s e ( h t t p : / / creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. (...truncated)


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1007%2Fs10637-017-0479-3.pdf

Jeffrey R. Infante, Roger B. Cohen, Kevin B. Kim, Howard A. Burris, Gregory Curt, Ugochi Emeribe, Delyth Clemett, Helen K. Tomkinson, Patricia M. LoRusso. Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors, Investigational New Drugs, 2017, pp. 669-669, Volume 35, Issue 5, DOI: 10.1007/s10637-017-0479-3